### Highlights of This Issue 2315

#### SPECIAL FEATURES

**CCR Translations**

- **2317** Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine
  Soumaya Karaki, Helene Pere, Cécile Badoual, and Eric Tartour
  
  See related article, p. 2342

- **2320** Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River
  Martin H. Voss and James J. Hsieh
  
  See related article, p. 2445

**CCR Perspectives in Regulatory Science and Policy**

- **2323** The Role of Neoadjuvant Trials in Drug Development for Solid Tumors
  Samuel A. Funt and Paul B. Chapman

#### Perspectives

- **2329** Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
  Masaki Mandai, Junzo Hamanishi, Kaoru Abiko, Noriomi Matsumura, Tsukasa Baba, and Ikuo Konishi

#### SPECIAL REPORT

- **2335** The Impact of Alternative Payment Models on Oncology Innovation and Patient Care
  Amy M. Miller, Gilbert S. Omenn, and Marcia A. Kean

---

#### CANCER THERAPY: CLINICAL

- **2342** Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
  
  See related commentary, p. 2317

- **2351** A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
  Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian J. Druker, Thomas O’Hare, Marc Ladanyi, and Monika A. Davare

- **2359** Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
  Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George Calvin, Susan O’Brien, Stefan Faderl, Xuemei Wang, William G. Wierda, Katayoun Rezvani, James M. Reuben, Jan A. Burger, Michael J. Keating, and Alessandra Ferrajoli

- **2368** A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
2482 A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma
Regina T. Martuscello, Vinata Vedam-Mai, David J. McCarthy, Michael E. Schmoll, Musa A. Jundi, Christopher D. Louviere, Benjamin G. Griffith, Colby L. Skinner, Oleg Suslov, Leïc P. Deleyrolle, and Brent A. Reynolds

2496 SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway
Claudia C.S. Chini, Jair M. Espindola-Netto, Gourish Mondal, Anaïlde M. Gonzalez Guerrico, Veronica Nin, Carlos Escande, Mauro Sola-Penna, Jin-San Zhang, Daniel D. Billadeau, and Eduardo N. Chini

2508 The New Antitumor Drug ABT0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Tatiana Erazo, Mar Lorente, Anna López-Planá, Pau Muñoz-Guardiola, Patricia Fernández-Nogueira, José A. García-Martínez, Paloma Bragado, Gemma Fuster, María Salazar, Jordi Espadaler, Javier Hernández-Losa, Jose Ramon Bayасcas, Marc Cortal, Laura Vidal, Pedro Gascon, Mariana Gómez-Ferreria, José Alfón, Guillermo Velasco, Carles Domènech, and Jose M. Lizcano

2520 Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression
Benjamin Ory, Marc Baudhuin, Franck Verrecchia, Bénédicte Brouais-Le Royer, Thibaut Quillard, Jérôme Amiaud, Séverine Battaglia, Dominique Heymann, Françoise Redini, and François Lamoureux

2534 The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects

2545 Silencing of CD24 Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer Cells
Wei Zhang, Bin Yi, Chao Wang, Dongguan Chen, Sejong Bae, Shi Wei, Rong-Jun Guo, Changming Lu, Lisa L.H. Nguyen, Wei-Hsiung Yang, James W. Lillard, Xingyi Zhang, Lishong Wang, and Runhua Liu

2555 Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression
Chiun Hsu, Liang-In Lin, Yu-Cheng Cheng, Zi-Rui Feng, Yu-Yun Shao, Ann-Li Cheng, and Da-Liang Ou

BIOLOGY OF HUMAN TUMORS

2565 Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer
Matthew R. Farren, Thomas A. Mace, Susan Geyer, Sameh Mikhail, Sethukkina Wu, Kristen Ciombor, Sanaz Tahiri, Daniel Ahr, Anne M. Noonan, Miguel Villalona-Calero, Tanios Bekaii-Saab, and Gregory B. Lesinski

2575 A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases

2583 Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer

LETTERS TO THE EDITOR

2594 The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Letter
Leticia G. Leon, Niccola Funel, Godefridus J. Peters, Amir Avan, Fabio Vistoli, Ulgo Bogg, and Elisa Giovannetti

2595 The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Response
Francesca Vena, John A. Hartley, and Daniel Hochhauser

CORRECTION

2596 Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
ABOUT THE COVER

The cover figure, which has been truncated, illustrates the results of unsupervised hierarchical clustering of gene-expression profiles of 86 out of the original 126 breast tumors for which there was residual disease after neoadjuvant chemotherapy. The clustering identified patients with an enhanced risk of recurrence who, predominantly, had disease that was ER-negative and/or highly proliferative (as evidenced by high Ki67). The first column from the left indicates the presence of recurrence; the second column, ER-positivity; the third column, HER2-positivity; and the last column, residual Ki67, ranging from 0 to 100%. For details, see the complete figure in the article by Klintman and colleagues on page 2405 of this issue.